Journal
BONE MARROW TRANSPLANTATION
Volume 28, Issue 8, Pages 787-789Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bmt.1703212
Keywords
germ cell tumor; rhabdomyosarcoma; tumor-adapted chemotherapy
Categories
Ask authors/readers for more resources
Treatment and prognosis have not been well characterized in germ cell tumors (GCT) with a malignant nongerm. cell component. Patients with a mediastinal tumor, neural or rhabdomyosarcomatous differentiation and distant metastases have the poorest prognosis. We report a rare case of mixed GCT composed of seminoma, teratoma and rhabdomyosarcoma with the rhabdomyosarcomatous component metastasized into the liver and bone marrow (BM) causing hypercalcemia. The patient was treated with differentiation-tailored chemotherapy (CHT) including a disease-adapted high-dose (HD) CHT regimen with purified autologous PBSCT (APBSCT) and pamidronate. To date, remission has lasted for 4 years. Tumor-adapted CHT including HD-CHT with APBSCT can induce long term remissions in high-risk patients with transformed GCT. A review of the literature is given.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available